@article{f6cb7b4b5b584067ae8027b685b594a3,
title = "Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions",
abstract = "Purpose of Review: This review focuses on recent evidence examining the role triglycerides (TG) and triglyceride-enriched lipoproteins (TGRL) play in atherosclerotic cardiovascular disease (ASCVD). It also provides a succinct overview of current and future TG-lowering therapies for ASCVD risk reduction. Recent Findings: Epidemiological and Mendelian randomization studies have consistently shown that TGRL are strongly associated with ASCVD. REDUCE-IT demonstrated cardiovascular benefit with icosapent ethyl in high-risk patients with hypertriglyceridemia on statin therapy. Polymorphisms in APOC3 and ANGPTL3 are associated with ASCVD and use of RNA-interfering therapies to target these proteins has shown TG lowering in early phase trials. Summary: TG and TGRL are causally associated with ASCVD. Lifestyle modifications and statin therapy can lower TG/TGRL and are considered first-line treatment for hypertriglyceridemia. Icosapent ethyl has been shown to reduce residual ASCVD risk in high-risk patients on maximally tolerated statins. Ongoing clinical trials will better define optimal therapy for patients on statins with residual hypertriglyceridemia.",
keywords = "Angiopoietin 3, Apolipoprotein C3, ASCVD, Omega-3 fatty acids, Triglyceride-rich lipoproteins, Triglycerides",
author = "Aliza Hussain and Ballantyne, {Christie M.} and Anum Saeed and Virani, {Salim S.}",
note = "Funding Information: Dr. Hussain has nothing to disclose. Dr. Saeed has nothing to disclose. Dr. Ballantyne has received National Institutes of Health grant R01HL134320; has received grants or research support (to his institution) from Abbott Diagnostic, Akcea, Amgen, Esperion, Novartis, Regeneron, and Roche Diagnostic; is a consultant for Abbott Diagnostics, Akcea, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc., Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo; and is named on provisional patent no. 61721475 “Biomarkers to Improve Prediction of Heart Failure Risk” filed by Baylor College of Medicine and Roche. Salim S. Virani reports research funding from the Department of Veterans Affairs, World Heat Federation and the Jooma and Tahir Family; Honorarium: American College of Cardiology (Associate Editor for Innovations, acc.org ); Steering Committee: Patient and Provider Assessment of Lipid Management (PALM registry) at the Duke Clinical Research Institute (no financial remuneration). Publisher Copyright: {\textcopyright} 2020, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.",
year = "2020",
month = jul,
day = "1",
doi = "10.1007/s11883-020-00846-8",
language = "English",
volume = "22",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "7",
}
